팝업레이어 알림
About Rznomics
Our vision is to treat/conquer various human intractable diseases such as hepatocellular carcinoma, intractable cancers, degenerative diseases and genetic diseases through development of innovative RNA-based biopharmaceutical.
About Rznomics
Excellence in Technology
-
Dual function in a single molecule
-
Modular Engineering
-
Disease-related RNA target specificity
-
High Performance
-
Continuous regulation of gene expression
Rznomics Pipeline
PIPELINE
Rznomics has core competencies to meet a variety of
unmet medical needs through development of
biopharmaceutical based on RNA platform
technology for cancer/intractable diseases.
NEWS & PRESS
Latest news about Rznomics or Stay informed about Rznomics
-
Rznomics to Lead Next-Generation Gene Therapy with Trans-splicing ...
Rznomics Inc. (CEO Seong-Wook Lee) held an Investor Relations (IR) conference on the 3rd December, ...
-
Rznomics to Participate in ‘BIO-Europe 2025’ to Expand Global ...
Rznomics Inc. announced on the 3rd November that it will officially participate in BIO-Europe 2025,...
-
Rznomics Receives Preliminary KOSDAQ Listing Approval
Rznomics Inc., a biotechnology company specializing in RNA-based gene therapeutics, officially anno...
- Head Office #801 Innovalley Bldg. C, 253, Pangyo-ro, Bundang-gu, Seongnam, 13486, Korea
- TEL. 031-706-8730
- FAX. 031-8018-8734
- E_mailrznomics@rznomics.com
- Research Institute#803(Research Institute) Innovalley Bldg. C, 253, Pangyo-ro, Bundang-gu, Seongnam, 13486, Korea
- TEL. 031-706-8730
Copyright(C) 2019 Rznomics. All Rights Reserved.
